Company Description
SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally.
It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.
The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion.
It markets its products primarily with a direct sales force, as well as through agents and resellers.
SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
Country | United States |
Founded | 2008 |
IPO Date | Oct 17, 2018 |
Industry | Medical Devices |
Sector | Healthcare |
Employees | 344 |
CEO | Ms. Laura A. Francis MBA |
Contact Details
Address: 471 El Camino Real, Suite 101 Santa Clara, California 95050 United States | |
Phone | (408) 207-0700 |
Website | si-bone.com |
Stock Details
Ticker Symbol | SIBN |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001459839 |
CUSIP Number | 825704109 |
ISIN Number | US8257041090 |
Employer ID | 26-2216351 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Laura A. Francis MBA | Chief Executive Officer and Director |
Anshul Maheshwari | Chief Financial Officer |
Anthony J. Recupero | President of Commercial Operations |
Jeff Bertolini | Senior Vice President of Operations and Information Technology |
Dr. Scott A. Yerby | Senior Vice President of Engineering and Chief Technology Officer |
Saqib Iqbal | Director of FP&A and Investor Relations |
Michael A. Pisetsky | Chief Business and Legal Affairs Officer |
Aimee Einstein | Vice President of People and Culture |
Dr. Daniel Joseph Cher | Senior Vice President of Clinical and Regulatory Affairs |
Dr. W. Carlton Reckling | Chief Medical Officer and Vice President of Medical Affairs |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 18, 2024 | PRE 14A | Other preliminary proxy statements |
Apr 3, 2024 | 144 | Filing |
Mar 14, 2024 | 144 | Filing |
Mar 13, 2024 | 144 | Filing |
Feb 27, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
Feb 27, 2024 | 10-K | Annual Report |
Feb 26, 2024 | 8-K | Current Report |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Feb 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |